Liju Zong

Liju Zong

Auto-generated profile, based on publicly available information

Liju Zong

Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2019 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
LZLiju Zong
Liju Zong
YZYuncan Zhou
Yuncan Zhou
MZMing Zhang
Ming Zhang
JCJie Chen
Jie Chen
YXYang Xiang
Yang Xiang
Blockading programmed death ligand 1 (PD-L1) shows promising results in patients with some cancers, but not in those with ovarian cancer. V-domain Ig suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint protein that suppresses T cell activation. This study aimed to investigate the expression and clinical significance of VISTA in ovarian cancer as well as its relationship with PD-L1. VISTA and PD-L1 levels in 146 ovarian cancer samples were assessed using immunohistochemistry. We investigated the association between VISTA and other clinicopathological variables, including survival. The associations between the VISTA-encoding C10orf54 gene, other immune checkpoints, and survival were analyzed. VISTA was detected in 51.4% of all samples and 46.6% of PD-L1-negative samples; it was expressed in 28.8%, 35.6%, and 4.1% of tumor cells (TCs), immune cells (ICs), and endothelial cells, respectively. Furthermore, VISTA expression was associated with pathologic type and PD-L1 expression. Moreover, VISTA expression in TCs, but not in ICs, was associated with prolonged progression-free and overall survival in patients with high-grade serous ovarian cancer. The expression of C10orf54 mRNA was associated with prolonged overall survival and immune escape-modulating genes. These results showed that VISTA expression in ovarian tumor cells was associated with a favorable prognosis in patients with high-grade serous ovarian cancer; however, additional studies are required to better understand the expression and role of VISTA in ovarian cancer.

7 April 2020 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
LZLiju Zong
Liju Zong
SMShengwei Mo
Shengwei Mo
SYShuangni Yu
Shuangni Yu
YZYuncan Zhou
Yuncan Zhou
MZMing Zhang
Ming Zhang
YXYang Xiang
Yang Xiang

1 June 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
LZLiju Zong
Liju Zong
YGYu Gu
Yu Gu
YZYuncan Zhou
Yuncan Zhou
YKYujia Kong
Yujia Kong
SMShengwei Mo
Shengwei Mo
JCJie Chen
Jie Chen

1 February 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
LZLiju Zong
Liju Zong
SMShengwei Mo
Shengwei Mo
ZSZezheng Sun
Zezheng Sun
ZLZhaohui Lu
Zhaohui Lu
SYShuangni Yu
Shuangni Yu
YXYang Xiang
Yang Xiang

1 January 2022 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
SYShuangni Yu
Shuangni Yu
ZSZezheng Sun
Zezheng Sun
LZLiju Zong
Liju Zong
JYJie Yan
Jie Yan
MYMei Yu
Mei Yu
ZLZhaohui Lu
Zhaohui Lu
Yu S, et al. J Gynecol Oncol. 2022 Feb;33(3):e38. https://doi.org/10.3802/jgo.2022.33.e38

9 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LZLiju Zong
Liju Zong
SMShengwei Mo
Shengwei Mo
ZSZezheng Sun
Zezheng Sun
ZLZhaohui Lu
Zhaohui Lu
JCJie Chen
Jie Chen
YXYang Xiang
Yang Xiang
Assessing survival risk in patients with high-grade endometrial carcinomas has remained challenging. We aimed to investigate the distribution of molecular subtypes and assess their prognostic role in a large cohort of 355 patients with high-grade endometrial carcinoma. Molecular classification was determined using DNA polymerase epsilon (POLE) sequencing as well as immunohistochemical staining for p53 and mismatch repair (MMR) proteins. Endometrial carcinomas were stratified into four subtypes: POLE ultramutated, MMR-deficient, non-specific molecular profile (NSMP), and p53-mutant. This study included 177 and 178 patients with endometrioid and non-endometrioid carcinomas, respectively. Forty-two patients (11.8%) were categorized as POLE ultramutated, 106 (29.9%) as MMR-deficient, 128 (36.1%) as p53-mutant, and 79 (22.2%) as NSMP. Patients of different molecular subtypes had distinct survival times; molecular classification, but not histotype, was significantly associated with survival outcomes. When incorporating molecular classification into the stratification model, 52 patients (15.5%) switched risk groups, with 40 (11.9%) shifting to a lower risk for having a POLE mutation and 12 (3.6%) shifting to a higher risk owing to p53-mutant status. Molecular classification may provide more accurate prognostic information among patients with high-grade endometrial carcinomas and improve their stratification for purposes of clinical management.